clinical cancer research

Advertisement

About Clinical Cancer Research

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.

Manuscript Submission

Clinical Cancer Research welcomes submissions of primary research, review and commentary article types as well as letters to the editor. . For descriptions and length requirements of the article types available to submitting authors, see the journal’s Categories of Articles .

The AACR Journals all use a similar Editorial Process and adhere to the same overarching Editorial Policies , both of which are detailed in the Instructions for Authors . These instructions contain important guidelines on authorship, publishing ethics, availability of materials and data, and data analysis and reporting. Authors should be familiar with these instructions prior to submitting their work to the journal.

Manuscripts are stringently reviewed for high standards of scientific merit, and only those that report results of novel, timely, and broadly-significant research are accepted for publication.

Journal Metrics

For detailed metrics about Clinical Cancer Research and the other AACR journals see the AACR Journals Metrics .

Editors and Editorial Board

Editorial oversight of Clinical Cancer Research and decisions on manuscripts submitted to the journal are the responsibility of the Editor-in-Chief and Executive Editor .

Copyright, Permissions and Access

Material published in Clinical Cancer Research is covered and protected by copyright. An author can either formally transfer copyright to the AACR, and be granted considerable reuse rights, or can publish an article as open access under a Creative Commons license. The final typeset version of every published article is rendered freely accessible 12 months after publication. In addition, the AACR assists authors in satisfying major funder Open Access archiving mandates by depositing the accepted author version of their article in a designated public repository. For additional details about all these topics, see Copyright, Permissions and Access .

Publication Fees

To defray publication costs and to support other AACR programs, publication in Clinical Cancer Research involves the payment of a base publication fee and an additional fee for each display item. If no financial support exists, authors may apply for a waiver of the fixed publication fee at the time of submission. See Publication Fees for further details.

Journal Information

Clinical Cancer Research (CCR) (Print ISSN: 1078-0432; Online ISSN: 1557-3265) is published twice a month, one volume/year, by the American Association for Cancer Research, Inc. (AACR).

Clinical Cancer Research is abstracted and/or indexed in MEDLINE, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.

Back Issues and Single Copy Sales

Subject to availability, single or back issues of Clinical Cancer Research may be purchased for $60 per copy in the U.S. or $65 per copy outside the U.S. For more information, contact:

AACR Publications Sales & Marketing Department American Association for Cancer Research 615 Chestnut Street, 17th Floor Philadelphia, PA 19106-4404 Phone: (215) 440-9300; or Toll Free: (855) 744-4667 E-mail: [email protected]

Clinical Cancer Research Editorial Office American Association for Cancer Research  |  Publications Division 615 Chestnut Street  |  17th Floor  |  Philadelphia, PA 19106-4404 Phone: (215) 440-9300  |  Fax: (215) 440-9354  |  E-mail:   [email protected]

• Online First
• Collections
• Online ISSN 1557-3265
• Print ISSN 1078-0432

AACR Journals

• Blood Cancer Discovery
• Cancer Discovery
• Cancer Epidemiology, Biomarkers & Prevention
• Cancer Immunology Research
• Cancer Prevention Research
• Cancer Research
• Cancer Research Communications
• Clinical Cancer Research
• Molecular Cancer Research
• Molecular Cancer Therapeutics
• Info for Advertisers
• Information for Institutions/Librarians

• Privacy Policy
• Copyright © 2023 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Clinical Trials Information for Patients and Caregivers

Explore the basics of clinical trials, including what they are, how they work, and what to expect. Learning all you can about clinical trials can help you talk with your doctor and decide what is right for you.

Find Clinical Trials

Find an NCI-supported clinical trial—and learn how to locate other research studies—that may be right for you or a loved one.

What Are Clinical Trials?

Learn about the purpose and importance of clinical trials, including the different types of clinical trials used in cancer research.

How Do Clinical Trials Work?

Learning how clinical trials work can help you decide if you want to join.

Who Pays for Clinical Trials?

Learn about the types of costs related to participating in a clinical trial, who is expected to pay for which costs, and tips for working with insurance companies.

Are Clinical Trials Safe?

Learn about the federal rules to help protect the rights and safety of people who take part in clinical trials. Learn about informed consent, institutional review boards, and how trials are closely monitored.

Why Participate in a Clinical Trial?

Learn about the possible risks and benefits of joining a clinical trial and questions to ask about trials.

National Cancer Institute - Cancer.gov

Clinical Research

Clinical-translational research at ccr.

One of CCR’s greatest strengths is our unmatched broad integration of basic and clinical scientists, where basic laboratories adjoin clinical wards. Thanks to this tight collaboration of researchers across disciplines and settings, we are uniquely able to knit together insights from preclinical disease models with science-based approaches to human clinical treatment.

Our collaborative model allows us to identify new cancer therapies, both single agents and combinations, and bring them rapidly through early development and clinical testing and, if successful, partner with extramural collaborators to ensure that they are quickly brought to widespread trials and hopefully into clinical practice. Our structure also enables us to find novel ways to detect cancer early and even prevent it, largely through building powerful new imaging technologies that allow us to “see” cancer even in its initial stages.

All CCR clinical trials take place at the NIH Clinical Center  located in Bethesda, Maryland, the world’s largest clinical research center. Our trials are open to patients, regardless of where they live in the United States

CCR's clinical-translational research program:

• Focuses on molecularly-guided patient care
• Integrates advanced biomedical technologies into every clinical trial
• Provides the infrastructure that enables bench-to-bedside-to-bench efforts
• Is committed to studying rare cancers and treating underserved patient populations
• Invests in new transformational technologies in genomics and imaging
• Is supported by the expertise and resources of the NIH Clinical Center

CCR Cancer Clinical Trials

To learn more about our clinical trials, cancer patients and their physicians should visit https://ccr.cancer.gov/clinical-trials .

Clinical Trials News

To learn about our latest clinical and translational research advances or our newest clinical trials currently recruiting patients, visit our News page.

Mayo Clinic Comprehensive Cancer Center — Research

• Adjunct Faculty
• About the Cancer Center
• Cancer Center Blog
• Research Programs
• Shared Resources: Core Facilities and Resources for Research
• Specialized Programs of Research Excellence (SPORE) Grants
• Support Cancer Research
• Early Cancer Therapeutics Group

Cancer Clinical Trials

Enhancing cancer care through clinical trials.

Adrienne, patient with breast cancer: Three words that really describe me I would say are bold, energetic and faithful.

Ronald, patient with prostate cancer: I would say that I try to be fair and honest.

Carol, patient with melanoma: Three words that describe me, I think, would be caring and compassionate. I think I'm loyal. And then I'm also very curious about things. I got the biopsy report before even seeing the doctor or anything. So I remember that moment very vividly because I read that and knew the seriousness of it.

Ronald: When I first got diagnosed, I thought it was like going down a dark alley and that's what I had pictured it. There were no lights. You didn't know where you were going, didn't know where you were going to end. But that was 19 years ago. So, I'm very grateful.

Adrienne: I felt all of the emotions; and most of all, I was really frightened about not being there for my daughter.

Matthew S. Block, M.D., Ph.D., medical oncologist: Often when a patient is diagnosed with cancer, they feel hopeless and scared. Clinical trials are one way that patients can be proactive. They can make a choice in how their care is going to be.

Geoffrey B. Johnson, M.D., Ph.D., nuclear radiologist: Clinical trials open the door to a new hope that maybe we can fight their cancer back and give them a better quality of life.

Judy C. Boughey, M.D., surgical oncologist: I think one common misperception about clinical trials is that if you enter a clinical trial, you may not get treatment. And that's actually very much not true. Most clinical trials are looking at one treatment compared to another treatment.

Carol: The trials provide an opportunity to feel like you're getting extra-special care. You're getting an extra-special dose of something that maybe wouldn't be available to you.

Dr. Boughey: We are very particular in how we select the clinical trials that we have available for patients. We want to have the best trials available for our patients. Some of the clinical trials are evaluating some of these drugs. We are so excited about those drugs, but we can't prescribe those drugs for patients without having that trial. And so we will actually fight to try to get that trial open here to have it available as an opportunity for our patients.

Adrienne: It is always patient first at Mayo, and they will always keep your health, your treatment at the center and what's best for you.

Ronald: We were always told upfront that if whenever we didn't think it was right, we could stop at any time. And I did truly believe that was true and trusted in them that I could stop whenever I wanted.

Dr. Boughey: For most patients that we evaluate, there's always the standard-of-care treatment option for those patients. And then in many situations, there's also a clinical trial that patient can participate in.

Carol: I've been in four different ones. This last trial had a little trigger in it that they're working with, and it seemed to make all the difference in the world. And so my prognosis of "You have 9 to 12 months" has totally changed.

Dr. Johnson: We couldn't advance medicine if it weren't for people volunteering for trials. And the promise from our side is to say we're not going to put patients on trials or offer trials for them to consider unless we think there's a good chance that they'll get a benefit or that society at large will get a benefit.

Adrienne: It wasn't lost on me that people before me, really bold, brave souls before me, said yes to clinical trials. So that the treatments and the medications and the courses that we all go through today are effective — and that can help save lives.

Dr. Boughey: So for any patients interested in clinical trials, it's definitely worth reaching out to your healthcare provider and asking, "What clinical trials could I be a potential candidate for?" And remember, you can ask this from your surgical oncologist, your medical oncologist, your radiation oncologist, any of the physicians that you're seeing. Because there are trials in all sorts of disciplines. There are also ongoing trials that require just collection of tissue or donation of blood that can also be important to try to help future generations as we continue to work to end cancer.

Carol: Thanks to my clinical trial, I've been given precious time to spend with family and friends, who are just the most dearest thing to me.

Ronald: I'm thankful that I did my clinical trial because I do believe I wouldn't be here if I hadn't tried it. I enjoy my grandkids, and that's the big part of this: I'll be around for a little longer, hopefully, and then this is why we do it.

Adrienne: I have always felt from day one until today that Mayo has kept me at the center and has always wanted what's best for me. And as a part of that, clinical trials was a way to provide me with cutting-edge treatments and provide me a way to also help others — and I am better for it.

Cancer clinical trials are a significant part of the care and services provided by Mayo Clinic Comprehensive Cancer Center. Clinical trials offer new options for patients from around the world seeking access to experimental procedures and drugs in all phases of development.

Hundreds of clinical trials are available at Mayo Clinic's three campuses in Arizona, Florida and Minnesota and at Mayo Clinic Health System sites in the Midwest. In addition, our Early Cancer Therapeutics Group offers access to phase I cancer trials.

Mayo Clinic Comprehensive Cancer Center also participates in the Minnesota Cancer Clinical Trials Network , a cancer clinical trials network with locations across Minnesota that aims to improve cancer outcomes for all Minnesotans through greater access to cancer clinical trials for prevention and treatment.

Learn more about cancer clinical trials at Mayo Clinic:

• Learn about cancer clinical trials .
• Read frequently asked questions about clinical trials .
• Get a list of all cancer clinical trials .
• Learn about our Early Cancer Therapeutics Group .
• Get a list of Early Cancer Therapeutics Group clinical trials (phase I) .
• Learn about the Clinical Research Office .

Contact Mayo Clinic

For more information about participating in cancer clinical trials at Mayo Clinic, contact:

• Clinical Trials Referral Office
• 855-776-0015 (toll-free)

More about research at Mayo Clinic

• Research Faculty
• Laboratories
• Core Facilities
• Centers & Programs
• Departments & Divisions
• Clinical Trials
• Institutional Review Board
• Postdoctoral Fellowships
• Training Grant Programs
• Publications

Mayo Clinic Footer

• Request Appointment
• About Mayo Clinic
• About This Site

Legal Conditions and Terms

• Terms and Conditions
• Privacy Policy
• Notice of Privacy Practices
• Notice of Nondiscrimination
• Manage Cookies

Advertising

Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.

• Advertising and sponsorship policy
• Advertising and sponsorship opportunities

Reprint Permissions

A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that publishes original research papers, reviews and commentaries in cancer research, from bench to bedside. Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer. Specific areas of interest include, but are not limited to: mechanisms of progression of the malignant phenotype and metastatic disease; molecular alterations or biomarkers that predict response or resistance to treatment; translational research in targeted therapies; personalized medicine; tumor immunotherapy; large-scale molecular characterization of human tumors and innovative methods with potential applicability to clinical investigation.

The following criteria provide an overview of the types of studies considered by the journal:

• Findings that have not been previously published in the same tumor model.
• Studies performed in multiple cell lines.
• Conclusions that are not representative of incremental findings.
• Studies that include a clearly written title and abstract that communicate the study's impact of significance to non-experts.

The online appearance of Journal of Experimental & Clinical Cancer Research allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.

Why publish your article in Journal of Experimental & Clinical Cancer Research ?

• We are published in partnership with the Association for International Promotion & Study in Tumors (APSIT) , and are committed to ensuring high visibility for your publication through dedicated social media support channels.
• We are a peer reviewed journal, ranked in the top quartile in Oncology , based on the 2021 JCR Impact Factors.
• Through open access publication, your article can be easily discovered, accessed, used and shared, maximising your impact and acting as a springboard for further discovery.
• Our rapid peer review process delivers a first decision within an average of 30 days, and 95% of our published authors reported that they would definitely or probably publish with us again.

Open access

All articles published by Journal of Experimental & Clinical Cancer Research are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here .

As authors of articles published in Journal of Experimental & Clinical Cancer Research you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement .

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article processing charges (APC)

Authors who publish open access in Journal of Experimental & Clinical Cancer Research are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £2890.00/$3990.00/€3390.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Indexing services

All articles published in Journal of Experimental & Clinical Cancer Research are included in:

• Current contents
• PubMed Central
• Science Citation Index Expanded

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink .

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here .

Journal of Experimental & Clinical Cancer Research  operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

After initial review for suitability, submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.

The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.

Editorial policies

All manuscripts submitted to Journal of Experimental & Clinical Cancer Research should adhere to BioMed Central's editorial policies .

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Citing articles in Journal of Experimental & Clinical Cancer Research

Articles in Journal of Experimental & Clinical Cancer Research should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. J Exp Clin Cancer Res [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Exp Clin Cancer Res 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies .

Benefits of publishing with BMC

High visibility.

Journal of Experimental & Clinical Cancer Research 's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Journal of Experimental & Clinical Cancer Research offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Journal of Experimental & Clinical Cancer Research gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed , to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Journal of Experimental & Clinical Cancer Research are included in article alerts and regular email updates. Some may be highlighted on Journal of Experimental & Clinical Cancer Research ’s pages and on the BMC homepage.

In addition, articles published in Journal of Experimental & Clinical Cancer Research may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Experimental & Clinical Cancer Research . A list of articles recently press-released by journals published by BMC is available here .

As an author of an article published in Journal of Experimental & Clinical Cancer Research you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement ).

For further information about the advantages of publishing in a journal from BMC, please click here .

Owned by the  Association for International Promotion & Study in Tumors (APSIT)

Official journal of the  Regina Elena National Cancer Institute , Scientific Director Gennaro Ciliberto, Rome, Italy

• Editorial Board
• Manuscript editing services
• Instructions for Editors
• Sign up for article alerts and news from this journal
• Submit manuscript

Annual Journal Metrics

2022 Citation Impact 11.3 - 2-year Impact Factor 11.5 - 5-year Impact Factor 1.870 - SNIP (Source Normalized Impact per Paper) 2.413 - SJR (SCImago Journal Rank)

2023 Speed 4 days submission to first editorial decision for all manuscripts (Median) 100 days submission to accept (Median)

2023 Usage  3,003,080 downloads 3,022 Altmetric mentions

• More about our metrics

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

• Submission enquiries: Access here and click Contact Us
• General enquiries: [email protected]